Oncolytics Biotech Showcases Pelareorep as Immune-Priming Backbone With New AACR 2026 Data

Oncolytics Biotech ( (ONCY) ) just unveiled an announcement.

Oncolytics Biotech will present new mechanistic and translational data at the AACR 2026 meeting showing that its lead candidate pelareorep acts as an immune-priming backbone, activating both innate and adaptive immunity and fostering tertiary lymphoid structure formation in tumors. These findings position pelareorep as a potential foundation for combination regimens with checkpoint inhibitors, targeted therapies, chemotherapy and other immuno-oncology agents across multiple tumor types.

New biomarker results from the Phase 1/2 GOBLET trial in metastatic pancreatic cancer indicate that pelareorep combined with atezolizumab and chemotherapy can convert tumors to a more immune-active state, with an immune activation signature at four weeks correlating with longer progression-free survival and previously reported response rates more than double historical chemotherapy benchmarks. Complementary data from the AWARE-1 breast cancer study show pelareorep can generate coordinated anti-tumor immune responses and tertiary lymphoid structures, suggesting it may sensitize immunologically cold or checkpoint-inhibitor–refractory tumors, including RAS-mutated cancers, thereby strengthening Oncolytics’ case for pelareorep as a versatile immune-priming strategy with broad clinical and commercial potential.

The most recent analyst rating on (ONCY) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.

Spark’s Take on ONCY Stock

According to Spark, TipRanks’ AI Analyst, ONCY is a Neutral.

The score is held back primarily by weak financial performance (no revenue, sizable losses, heavy cash burn, and a sharply reduced equity base that raises financing risk). Technicals are a near-term positive with price above major moving averages and positive momentum indicators, while valuation remains difficult to support due to the negative P/E and lack of dividend.

To see Spark’s full report on ONCY stock, click here.

More about Oncolytics Biotech

Oncolytics Biotech Inc. is a clinical-stage immunotherapy company focused on developing pelareorep, an investigational, systemically delivered viral therapy designed to prime anti-tumor immune responses. The company targets difficult-to-treat solid tumors, including breast and gastrointestinal cancers, with an emphasis on RAS-driven malignancies such as pancreatic and colorectal cancer.

Average Trading Volume: 1,343,466

Technical Sentiment Signal: Sell

Current Market Cap: $103.4M

See more data about ONCY stock on TipRanks’ Stock Analysis page.